Safety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies
dc.contributor.author | Gammon, David C. | |
dc.contributor.author | Lizotte, Margaret W. | |
dc.date | 2022-08-11T08:08:06.000 | |
dc.date.accessioned | 2022-08-23T15:42:29Z | |
dc.date.available | 2022-08-23T15:42:29Z | |
dc.date.issued | 2004-07-27 | |
dc.date.submitted | 2010-03-10 | |
dc.identifier.citation | <p>J Infus Nurs. 2004 Jul-Aug;27(4):251-3.</p> | |
dc.identifier.issn | 1533-1458 (Linking) | |
dc.identifier.pmid | 15273632 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/26858 | |
dc.description.abstract | This study challenges the current practice of administering paclitaxel for a variety of malignancies over 3 hours and documents the safety and cost-effectiveness of 1-hour administration in the outpatient setting. The authors investigated opportunities to save nursing time and costs in a cancer clinic without compromising patient safety. These savings are referred to as "opportunity-cost savings" that enable the clinic to schedule more patients during the time normally required to administer a 3-hour paclitaxel dose. Over a 2-year period, the authors were able to document significant time savings with no increase in adverse drug reactions. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15273632&dopt=Abstract">Link to Article in PubMed</a></p> | |
dc.relation.url | https://insights.ovid.com/pubmed?pmid=15273632 | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Cost-Benefit Analysis | |
dc.subject | Female | |
dc.subject | *Health Care Costs | |
dc.subject | Humans | |
dc.subject | Infusions, Intravenous | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Neoplasms | |
dc.subject | Paclitaxel | |
dc.subject | *Safety | |
dc.subject | Time Factors | |
dc.subject | Pharmacy and Pharmaceutical Sciences | |
dc.title | Safety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies | |
dc.type | Journal Article | |
dc.source.journaltitle | Journal of infusion nursing : the official publication of the Infusion Nurses Society | |
dc.source.volume | 27 | |
dc.source.issue | 4 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/clinpharm_pp/5 | |
dc.identifier.contextkey | 1212964 | |
html.description.abstract | <p>This study challenges the current practice of administering paclitaxel for a variety of malignancies over 3 hours and documents the safety and cost-effectiveness of 1-hour administration in the outpatient setting. The authors investigated opportunities to save nursing time and costs in a cancer clinic without compromising patient safety. These savings are referred to as "opportunity-cost savings" that enable the clinic to schedule more patients during the time normally required to administer a 3-hour paclitaxel dose. Over a 2-year period, the authors were able to document significant time savings with no increase in adverse drug reactions.</p> | |
dc.identifier.submissionpath | clinpharm_pp/5 | |
dc.contributor.department | Department of Pharmacy | |
dc.source.pages | 251-3 |